Skip to content
value.today

Palisade Bio, Inc.

PALI
$215 Mmarket cap on Oct 28, 2026+4202.6% since Jan 2024
Compare
World rank
#15,982
Revenue
$0 M
For year ending December-2025
value.today research
Net income
$-17 M
value.today research
Employees
14
As of March 18, 2026
SEC filing

Palisade Bio, Inc. in brief

Palisade Bio, Inc. is a listed company in the Biotechnology industry, based in Maryland, USA. Its market value was $215 M on 28 October 2026, which makes it the 15,982nd largest listed company in the world and the 3,111th largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $17 M. It employs about 14 people and J.D. Finley is its chief executive. Its shares trade under the symbol PALI (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Palisade Bio, Inc.

We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.

We are committed to advancing a next generation of once daily, oral PDE4 inhibitor prodrugs to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases.

We are developing a biomarker-based patient selection approach that we believe may aid clinicians in identifying patients who may better respond to PALI-2108, thereby improving the rate of clinical response previously demonstrated with PDE4 inhibitors. Our approach involves the use of clinical and multiomics data from large patient populations to identify PDE4-related biomarkers that are correlated with IBD, its severity, and which are modified with local PDE4-inhibitor therapy in the colon. Based on our research, we have initiated the development of corresponding biomarker assays for these PDE4-related biomarkers that we expect to use in our current and future clinical studies with the aim of developing regulatory approved tests for selecting potential responders to PALI-2108.

From the company's annual report filed with the US SEC: read the report

Palisade Bio, Inc. timeline

3 events, 2006–2021
  1. 2006
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2020
  4. ✎
    Renamed Seneca Biopharma, Inc.
    Formerly Neuralstem, Inc..
  5. 2021
  6. ✎
    Renamed Palisade Bio, Inc.
    Formerly Seneca Biopharma, Inc..

Events of Palisade Bio, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$101 M$201 M$302 M$403 M2023202420252026

World rank over time

▲ up 14,467 places since 2022
2022-01-07: #30495#30,49520222022-12-25: #33543#33,54320222023-07-30: #30492#30,49220232024-01-05: #32314#32,31420242026-03-08: #8683#8,68320262026-08-01: #13389#13,38920262026-10-14: #15369#15,36920262026-10-28: #16028#16,0282026

Rank in USA: #5,441 (Jan 2022) · #5,847 (Dec 2022) · #5,293 (Jul 2023) · #4,630 (Jan 2024) · #1,617 (Mar 2026) · #2,718 (Aug 2026) · #2,972 (Oct 2026) · #3,115 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.7×
Free cash flow yield
-5.7%
Net margin
—
Operating margin
—
Return on equity
-13.0%
Liabilities / assets
3.7%
Net debt
$-10M
Revenue growth
+2400.0%
R&D / revenue
2756.0%
Revenue per employee
$0 K
Profit per employee
$-1.2 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $0M, net income $-5M$0MFY18Fiscal year ending Dec 2019: revenue $0M, net income $-8M$0MFY19Fiscal year ending Dec 2020: revenue $0M, net income $-10M$0MFY20Fiscal year ending Dec 2021: revenue —, net income $-27M—FY21Fiscal year ending Dec 2022: revenue —, net income $-14M—FY22Fiscal year ending Dec 2023: revenue $0M, net income $-12M$0MFY23Fiscal year ending Dec 2024: revenue —, net income $-14M—FY24Fiscal year ending Dec 2025: revenue —, net income $-17M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-18M$-17M—
Dec 2024——$-15M$-14M—
Dec 2023$0M—$-13M$-12M-4920.0%
Dec 2022——$-16M$-14M—
Dec 2021——$-42M$-27M—
Dec 2020$0M-50.0%$-9M$-10M-103200.0%
Dec 2019$0M-92.3%$-9M$-8M-41750.0%
Dec 2018$0M—$-8M$-5M-1892.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-11M——$-0.30—
Dec 2024$-12M$0M$-12M$-10.19—
Dec 2023$-11M$0M$-11M$-27.01—
Dec 2022$-13M$0M$-13M$-16.53—
Dec 2021$-15M$0M$-15M$-169.74—
Dec 2020$-5M$0M$-5M$-3.72—
Dec 2019$-7M——$-3.80—
Dec 2018$-8M$0M$-8M$-7.54—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-3M—Dec ’24Three months to Mar 2025: revenue —, net income $-2M—Mar ’25Three months to Jun 2025: revenue —, net income $-3M—Jun ’25Three months to Sep 2025: revenue —, net income $-3M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-9M—Dec ’25Three months to Mar 2026: revenue —, net income $-10M—Mar ’26Three months to Jun 2026: revenue $1M, net income $-11M$1MJun ’26Three months to Sep 2026: revenue —, net income $-15M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-15M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Palisade Bio, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-18 M
Net income
$-17 M

For year ending December-2025

Balance sheet

Total assets
$134 M
Total liabilities
$5 M
Total equity
$129 M

As of December-2025

Top 100 institutional investors in Palisade Bio, Inc.#

As of Sep 30, 2026
116 institutions held 177.9 M shares (about 99.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 57.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Palisade Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Soleus Capital Management, L.P.14,996,154+1,932,467 (+14.79%)8.36%$20 MNov 16, 2026
2Ameriprise Financial Inc14,567,993+3,486,559 (+31.46%)8.13%$20 MNov 16, 2026
3B Group, Inc.11,414,2850 (0.00%)6.37%$15 MNov 16, 2026
4BlackRock, Inc.11,095,890+659,130 (+6.32%)6.19%$15 MNov 13, 2026
5Janus Henderson Group Ltd.10,689,452—5.96%$14 MNov 16, 2026
6Octagon Capital Advisors LP10,276,3170 (0.00%)5.73%$14 MNov 16, 2026
7Perceptive Advisors LLC8,425,0650 (0.00%)4.70%$11 MNov 16, 2026
8Vanguard Capital Management LLC7,888,020+6,165,203 (+357.86%)4.40%$11 MNov 13, 2026
9Ra Capital Management, L.P.7,124,1160 (0.00%)3.97%$10 MNov 16, 2026
10Franklin Templeton Inc6,069,746+284,557 (+4.92%)3.39%$8 MNov 12, 2026
11Point72 Asset Management, L.P.5,873,267+619,864 (+11.80%)3.28%$8 MNov 16, 2026
12Wellington Management Group LLP5,410,568+1,706,632 (+46.08%)3.02%$7 MNov 16, 2026
13Boxer Capital Management, LLC4,799,8750 (0.00%)2.68%$6 MNov 16, 2026
14Adage Capital Partners GP, L.L.C.4,500,0000 (0.00%)2.51%$6 MNov 16, 2026
15Geode Capital Management, LLC3,858,682+98,197 (+2.61%)2.15%$5 MNov 6, 2026
16Eversept Partners, LP3,474,548-708,237 (-16.93%)1.94%$5 MNov 16, 2026
17Federated Hermes, Inc.3,136,6070 (0.00%)1.75%$4 MNov 12, 2026
18Squadron Capital Management LLC3,000,0000 (0.00%)1.67%$4 MNov 16, 2026
19State Street Corp2,933,459+457,811 (+18.49%)1.64%$4 MNov 12, 2026
20Goldman Sachs Group Inc2,719,130-858,890 (-24.00%)1.52%$4 MNov 16, 2026
21Vestal Point Capital, LP2,500,0000 (0.00%)1.39%$3 MNov 16, 2026
22Sphera Funds Management LTD.2,464,038+206,932 (+9.17%)1.37%$3 MNov 16, 2026
23Silverarc Capital Management, LLC2,335,602New1.30%$3 MNov 12, 2026
24Aberdeen Group plc2,276,844+366,639 (+19.19%)1.27%$3 MNov 10, 2026
25Propel Bio Management, LLC2,224,189-358,199 (-13.87%)1.24%$3 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Palisade Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Platinum Investment Management LTD2,184,388+453,522 (+26.20%)1.22%$3 MNov 16, 2026
27Los Angeles Capital Management LLC2,130,631+2,072,246 (+3549.28%)1.19%$3 MNov 12, 2026
28Siren, L.L.C.2,000,0000 (0.00%)1.12%$3 MNov 12, 2026
29ADAR1 Capital Management, LLC1,541,747-184,915 (-10.71%)0.86%$2 MNov 16, 2026
30Vanguard Portfolio Management LLC1,442,126+448,031 (+45.07%)0.80%$2 MNov 13, 2026
31Northern Trust Corp1,250,733+53,113 (+4.43%)0.70%$2 MNov 16, 2026
32HighVista Strategies LLC1,151,082-879,845 (-43.32%)0.64%$2 MNov 13, 2026
33Vanguard Fiduciary Trust Co1,117,461+231,549 (+26.14%)0.62%$2 MNov 13, 2026
34UBS Group AG1,078,227+340,920 (+46.24%)0.60%$1 MNov 10, 2026
35Millennium Management LLC917,062-17,093 (-1.83%)0.51%$1 MNov 16, 2026
36Creek Drive Management Group LLC680,000+240,000 (+54.55%)0.38%$1 MNov 10, 2026
37BIT Capital GmbH679,000+105,000 (+18.29%)0.38%$1 MNov 13, 2026
38Nuveen, LLC524,637-444,820 (-45.88%)0.29%$1 MNov 10, 2026
39Atom Investors LP516,922New0.29%$1 MNov 16, 2026
40Charles Schwab Investment Management Inc456,845+21,862 (+5.03%)0.25%$1 MNov 16, 2026
41Simplify Asset Management Inc.434,333-16,210 (-3.60%)0.24%$1 MOct 27, 2026
42Susquehanna International Group, LLP426,747+395,842 (+1280.83%)0.24%$1 MNov 16, 2026
43Ikarian Capital, LLC400,000-350,000 (-46.67%)0.22%$1 MNov 16, 2026
44Bank of New York Mellon Corp368,417+19,948 (+5.72%)0.21%$0 MNov 5, 2026
45Balyasny Asset Management L.P.357,914-1,517,780 (-80.92%)0.20%$0 MNov 16, 2026
46XTX Topco Ltd346,581+216,318 (+166.06%)0.19%$0 MNov 16, 2026
47Boothbay Fund Management, LLC324,022-113,115 (-25.88%)0.18%$0 MNov 16, 2026
48ACT Capital Partners, L.P.307,500—0.17%$0 MNov 6, 2026
49Voleon Capital Management LP274,348+255,501 (+1355.66%)0.15%$0 MNov 16, 2026
50Seven Fleet Capital Management LP272,2040 (0.00%)0.15%$0 MNov 16, 2026
51American Century Companies Inc205,883+81,192 (+65.11%)0.11%$0 MNov 12, 2026
52Rhumbline Advisers172,442+11,669 (+7.26%)0.10%$0 MNov 10, 2026
53Persistent Asset Partners Ltd138,953+97,489 (+235.12%)0.08%$0 MNov 13, 2026
54Bank Of America Corp /de/131,682-42,179 (-24.26%)0.07%$0 MNov 16, 2026
55Deutsche Bank AG\125,924-18,076 (-12.55%)0.07%$0 MNov 6, 2026
56Price T Rowe Associates Inc /MD/121,1520 (0.00%)0.07%$0 MNov 16, 2026
57Morgan Stanley115,433-2,358,636 (-95.33%)0.06%$0 MNov 13, 2026
58Pale Fire Capital SE111,4100 (0.00%)0.06%$0 MNov 13, 2026
59Creative Planning91,474New0.05%$0 MNov 2, 2026
60LPL Financial LLC88,004-54,150 (-38.09%)0.05%$0 MNov 6, 2026
61Sectoral Asset Management Inc88,0000 (0.00%)0.05%$0 MNov 13, 2026
62China Universal Asset Management Co., Ltd.81,000+13,110 (+19.31%)0.05%$0 MOct 28, 2026
63Jpmorgan Chase & Co78,303+13,588 (+21.00%)0.04%$0 MNov 12, 2026
64Invesco Ltd.72,499-4,899 (-6.33%)0.04%$0 MNov 12, 2026
65MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.71,331+3,657 (+5.40%)0.04%$0 MNov 16, 2026
66Diadema Partners LP69,533New0.04%$0 MNov 16, 2026
67Vanguard Global Advisers, LLC67,615+15,323 (+29.30%)0.04%$0 MNov 13, 2026
68MetLife Investment Management, LLC66,015-21,860 (-24.88%)0.04%$0 MNov 16, 2026
69Barclays PLC58,743+22,490 (+62.04%)0.03%$0 MNov 6, 2026
70Alliancebernstein L.P.52,0400 (0.00%)0.03%$0 MNov 16, 2026
71Police & Firemen's Retirement System of New Jersey43,5300 (0.00%)0.02%$0 MNov 9, 2026
72Manufacturers Life Insurance Company, The41,554+1,422 (+3.54%)0.02%$0 MNov 13, 2026
73PCG Wealth Advisors, LLC41,1000 (0.00%)0.02%$0 MNov 10, 2026
74BNP Paribas Financial Markets37,407+14,857 (+65.88%)0.02%$0 MNov 12, 2026
75New York State Common Retirement Fund33,1000 (0.00%)0.02%$0 MNov 17, 2026
76Wells Fargo & Company/mn32,731-92,836 (-73.93%)0.02%$0 MNov 16, 2026
77Voya Investment Management LLC29,672+1,529 (+5.43%)0.02%$0 MNov 10, 2026
78Panagora Asset Management Inc24,143New0.01%$0 MNov 12, 2026
79AQR Capital Management LLC23,881New0.01%$0 MNov 16, 2026
80Prudential Financial Inc22,2650 (0.00%)0.01%$0 MNov 16, 2026
81NFSG Corp20,2500 (0.00%)0.01%$0 MOct 15, 2026
82PFG Investments, LLC20,000New0.01%$0 MNov 12, 2026
83ProShare Advisors LLC19,213-112 (-0.58%)0.01%$0 MOct 29, 2026
84Victory Capital Management Inc18,792-965 (-4.88%)0.01%$0 MNov 10, 2026
85Royal Bank Of Canada18,185+13,617 (+298.10%)0.01%$0 MNov 16, 2026
86Landscape Capital Management, L.L.C.17,922-418,804 (-95.90%)0.01%$0 MNov 10, 2026
87Wealth Enhancement Advisory Services, LLC17,235-11,993 (-41.03%)0.01%$0 MOct 13, 2026
88CIBC Bancorp USA Inc.17,128+6,980 (+68.78%)0.01%$0 MNov 13, 2026
89Choreo, LLC15,7430 (0.00%)0.01%$0 MOct 28, 2026
90Squarepoint Ops LLC14,636-71,342 (-82.98%)0.01%$0 MNov 9, 2026
91Legal & General Group Plc14,3230 (0.00%)0.01%$0 MNov 16, 2026
92WINTON GROUP Ltd14,300-17,927 (-55.63%)0.01%$0 MNov 12, 2026
93Xponance LLC13,822-244 (-1.73%)0.01%$0 MNov 3, 2026
94Ameritas Investment Partners, Inc.13,3950 (0.00%)0.01%$0 MNov 13, 2026
95Kestra Advisory Services, LLC12,5040 (0.00%)0.01%$0 MNov 2, 2026
96Russell Investments Group, Ltd.11,7700 (0.00%)0.01%$0 MNov 6, 2026
97Public Employees Retirement System Of Ohio11,737New0.01%$0 MNov 16, 2026
98Global Retirement Partners, LLC10,389New0.01%$0 MNov 10, 2026
99Osaic Holdings, Inc.10,066+10,000 (+15151.52%)0.01%$0 MNov 12, 2026
100SBI Securities Co., Ltd.10,000New0.01%$0 MOct 22, 2026

All 116 institutional investors, with who bought and sold →

Mutual funds holding Palisade Bio, Inc.#

63 funds hold shares worth $42 M (about 11.7% of the company). Since their previous reports 56 added shares and 2 sold, buying $25 M net.
Mutual funds holding Palisade Bio, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors3.73 M$8 M2.1%<0.01%newJun 30, 2026
🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company3.14 M$6 M1.7%0.21%no changeJul 31, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.2.12 M$4 M1.2%0.35%no changeJul 31, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.1.91 M$4 M1.1%0.58%+188%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.72 M$4 M0.96%<0.01%+21%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.61 M$3 M0.90%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors1.12 M$2 M0.62%0.02%newJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC773,196$1 M0.43%<0.01%newJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC667,004$1 M0.37%<0.01%−1.6%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors495,848$1 M0.28%0.07%newJun 30, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors380,673$1 M0.21%<0.01%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.358,983$1 M0.20%<0.01%newJul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC275,899$1 M0.15%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC269,212$1 M0.15%<0.01%no changeMay 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors246,405$1 M0.14%<0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC196,088$0 M0.11%<0.01%−15%May 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC196,261$0 M0.11%<0.01%newJul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC169,895$0 M0.09%0.02%newJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC159,559$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation108,700$0 M0.06%0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC99,684$0 M0.06%<0.01%+11%May 31, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.101,600$0 M0.06%0.02%newJul 31, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC84,945$0 M0.05%0.01%+3.9%Jun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust80,446$0 M0.04%<0.01%newMay 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.76,393$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.76,000$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC70,212$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC49,821$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.47,400$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS45,286$0 M0.03%0.04%newJun 30, 2026
🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.43,055$0 M0.02%0.04%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC42,319$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC33,326$0 M0.02%0.03%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC32,829$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS32,756$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Multi-Manager U.S. Small Cap Equity FundGoldman Sachs Asset Management, L.P.32,796$0 M0.02%0.02%—Apr 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC30,635$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC26,020$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC26,020$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC24,895$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC25,851$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.23,150$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.22,254$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC19,964$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC18,775$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.19,757$0 M0.01%<0.01%+20%Jul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC17,869$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC17,284$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management13,395$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS13,052$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC11,770$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC10,274$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC9,090$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC9,875$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS8,255$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC6,653$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC5,184$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC5,164$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC3,882$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.3,726$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC2,692$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC2,340$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC2,009$0 M<0.01%<0.01%newJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 63 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Palisade Bio, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$297 K
10 purchases, 2 insiders
Sold, 12 months
$421 K
4 sales, 2 insiders
Net, 12 months
-$124 K
open market only
Insiders on file
25
since
$250 K-$410 K$0Jan 2024: bought $12 K (2 trades), sold $0 (0 trades)Jan 24Feb 2024: bought $5 K (1 trades), sold $0 (0 trades)FebMay 2024: bought $10 K (2 trades), sold $0 (0 trades)MayJan 2026: bought $18 K (2 trades), sold $0 (0 trades)Jan 26Feb 2026: bought $0 (0 trades), sold $10 K (2 trades)FebJul 2026: bought $250 K (6 trades), sold $410 K (2 trades)JulOct 2026: bought $29 K (2 trades), sold $0 (0 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
Palisade Bio, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Julien E. CapersSee RemarksGrant or award+787,300——787,300Form 4
filed Mitchell Lawrence JonesSee RemarksOption exercise+2.62 M——2.71 MForm 4
filed John David FinleyCEO CFO, DirectorOption exercise+3.23 M——3.36 MForm 4
filed Mitchell Lawrence JonesSee RemarksShares withheld for tax-1.03 M$1.490$1.5 M1.68 MForm 4
filed John David FinleyCEO CFO, DirectorShares withheld for tax-1.41 M$1.490$2.1 M1.94 MForm 4
filed Donald Allen WilliamsDirectorBuy+10,000$1.460$15 K1.59 MForm 4
filed Donald Allen WilliamsDirectorBuy+10,000$1.420$14 K1.58 MForm 4
filed John David FinleyCEO, CFO, DirectorGift-88,400——129,288Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Palisade Bio, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
29.3 M
18.4% of shares · 7.76 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2024-12-12 17:05 UTC, code LUDP, resumed 17:10 UTC

Fails to deliver

  • : 12,907 shares at $1.20
  • : 97,283 shares at $1.23
  • : 4,140 shares at $1.41
  • : 6,017 shares at $1.54
  • : 14,204 shares at $1.47

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Palisade Bio, Inc. scorecard#

Passes 2 of the 11 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.7×Price to book 1.7× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-5.7%Free cash flow is -5.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.30 vs -10.19Diluted EPS -0.30 in fiscal 2025 against -10.19 the year before (report's currency).
    • ✗Net income higher than five years earlier-$17 M-$17 M in fiscal 2025 against -$10 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$17 MNet income -$17 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-24.5%-24.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities28.9×Current ratio 28.93 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Palisade Bio, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Palisade Bio, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue000.30—0.00.00.30.30.0
Research and development1016r6.96.52.42.04.14.08.113
General and administrative7.95.86.28.89.36.2r4.64.65.57.5
Operating expenses18151316429.3r8.68.51421
Operating income−18−15−13−16−42−9.3r−8.6−8.3−13−21
Interest and finance income—————0.00.10.10.10.1
Interest expense and finance costs0.00.00.00.02.40.2r0.00.00.21.1
Other non-operating income (expense)1.30.40.81.515−1.0r0.33.3−2.4−0.4
Income tax000000.0———0
Net income attributable to shareholders−17−14−12−14−27−10r−8.4−4.9−16−21
Earnings per share, basic-0.30-10.19-27.01r-16.53-142.95r-3.72r-3.80-7.54r-1.20-2.53
Earnings per share, diluted-0.30-10.19-27.01r-16.53-169.74r-3.72r-3.80-7.54r-1.20-2.53
Shares, weighted average (basic)561.40.5r0.90.2r2.8————
Shares, weighted average (diluted)561.40.5r0.90.2r2.8r2.20.7r138.3
Balance sheet
Cash and cash equivalents1339.81212100.7r5.15.86.715
Short-term investments————————5.05.0
Receivables00—000.1r0.00.30.30.0
Other current assets0.80.70.92.41.0r0.1————
Current assets13410131512r0.9r5.66.51221
Property, plant and equipment00.00.00.00.00.0r0.00.10.20.3
Right-of-use (leased) assets00.10.20.30.10.30.2———
Other intangible assets—————0.10.70.80.91.0
Total assets134111416133.0r6.67.71423
Accounts payable0.81.10.71.81.32.5————
Debt due within a year————0.11.0———3.7
Current liabilities4.63.22.63.02.58.1r1.21.11.57.3
Long-term debt————00.1————
Lease liabilities (non-current)—00.10.200.10.1———
Non-current liabilities0.3—————————
Total liabilities5.03.42.73.35.110r1.51.65.411
Retained earnings—13612210995−68r−222−214−209−193
Shareholders' equity1297.511127.4−17r−8.3r6.08.511
Total liabilities and equity134111416133.0r6.67.71423
Shares outstanding1592.80.6r2.90.3r2.8r3.90.9r1511
Cash-flow statement
Depreciation and amortization———0.00.00.0r0.10.20.30.3
Share-based compensation4.00.70.61.01.92.0r0.90.61.83.4
Cash from operating activities−11−12−11−13−15−4.8r−7.3−7.7−13−16
Capital expenditure—0−0.0−0.00−0.0—−0.0−0.0−0.1
Intangible assets bought————————−0.1−0.1
Cash from investing activities—0−0.0−0.0−0.1−0.0—5.0−0.12.4
Debt repaid————————−3.8−4.6
Shares issued1288.49.4145.21.2————
Cash from financing activities1349.61115251.9r6.61.85.024
Exchange-rate effect on cash——————−0.0−0.0−0.0−0.0
Change in cash124−2.60.01.99.8−2.9r−0.7−0.9−8.510
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Palisade Bio, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$18.8 M
J.D. Finley
Other top executives, average
—
$100 invested is now
$3
Palisade Bio, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025J.D. Finley$18.8 M$22.7 M—$3
2024J.D. Finley$813 K$692 K—$2
2023J.D. Finley$1.3 M$1.0 M—$11

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Palisade Bio, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 5 · Material agreement 3 · Unregistered share sale 2 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 3

Palisade Bio, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Directors and officers8-K
Shareholder vote8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Delisting notice8-K
Material agreementUnregistered share sale8-K
Directors and officersMaterial agreement8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Palisade Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2024$4 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Feb 2024$3 MPrivate placement after listing$2 to $10 million15optionsSEC
Apr 2023$4 MPrivate placement after listing$2 to $10 million9equity, optionsSEC
Jan 2023$3 MPrivate placement after listing$2 to $10 million6optionsSEC
May 2022$2 MPrivate placement after listing$2 to $10 million5optionsSEC
Jan 2020$8 MPrivate placement after listing$2 to $10 million3optionsSEC
Dec 2016$20 MPrivate placement after listing$10 to $50 million1equitySEC
May 2016$1 MPrivate placement after listingUnder $2 million3equity, optionsSEC
Oct 2014$10 MPrivate placement after listing$10 to $50 million1debt, optionsSEC
Mar 2013$2 MPrivate placement after listingUnder $2 million3equity, debt, optionsSEC
Dec 2009$2 MNo. 1Under $2 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Palisade Bio, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2016–2022
Latest
—
2022-09-15
Palisade Bio, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2022············—
2016············—
Palisade Bio, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Palisade Bio, Inc. compares in Biotechnology

  • Market cap$215 M · higher than 45% of 726
  • Revenue$0 M · higher than 0% of 647
  • Price / book1.7× · lower than 63% of 534
  • FCF yield-5.7% · higher than 69% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Palisade Bio, Inc.🇺🇸$215 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 18, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, value.today research, SEC filing, SEC annual report, GLEIF register.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Palisade Bio, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Palisade Bio, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Palisade Bio, Inc.? Suggest a correction